Enanta Pharmaceuticals 향후 성장

Future 기준 점검 1/6

Enanta Pharmaceuticals은 연간 수입과 매출이 각각 23.9%와 17.5% 증가할 것으로 예상되고 EPS는 연간 29.9%만큼 증가할 것으로 예상됩니다.

핵심 정보

23.9%

이익 성장률

29.91%

EPS 성장률

Biotechs 이익 성장	25.4%
매출 성장률	17.5%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	19 May 2026

최근 향후 성장 업데이트

분석 기사 • May 13

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

The quarterly results for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) were released last week, making it a good time...

분석 기사 • Feb 12

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) investors will be delighted, with the company turning in some strong...

Recent updates

분석 기사 • May 13

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

The quarterly results for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) were released last week, making it a good time...

분석 기사 • Feb 12

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) investors will be delighted, with the company turning in some strong...

분석 기사 • Dec 20

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have been powering on, with a gain...

분석 기사 • Nov 26

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

분석 기사 • Oct 30

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30%

The Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) share price has softened a substantial 30% over the previous 30 days...

Seeking Alpha • Sep 29

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Summary Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically significant improvements in PGI-S scores and viral load reduction, supporting potential for phase 3 advancement pending FDA feedback. Strong cash position funds operations into 2028, with ongoing MAVYRET/MAVIRET royalties and a manageable quarterly cash burn. Upcoming catalysts include an end-of-phase 2 FDA meeting for zelicapavir and continued pipeline expansion with STAT6 and KIT inhibitor programs. Read the full article on Seeking Alpha

분석 기사 • Sep 03

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27%

The Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) share price has done very well over the last month, posting an...

분석 기사 • Aug 14

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) just released its latest quarterly results and things are looking bullish...

분석 기사 • May 18

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Investors in Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) had a good week, as its shares rose 9.1% to close at US$5.75...

분석 기사 • Mar 31

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders won't be pleased to see that the share price has had a very...

분석 기사 • Feb 14

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders are no doubt pleased to see that the share price has bounced...

분석 기사 • Nov 30

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

The analysts might have been a bit too bullish on Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), given that the company...

분석 기사 • Nov 27

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

To the annoyance of some shareholders, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares are down a considerable 27...

분석 기사 • Oct 05

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

분석 기사 • Aug 08

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

A week ago, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) came out with a strong set of third-quarter numbers that could...

분석 기사 • Jul 24

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have had a really impressive month, gaining 26% after a shaky...

분석 기사 • Jun 19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

분석 기사 • May 09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Shareholders might have noticed that Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) filed its quarterly result this time...

분석 기사 • Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Despite an already strong run, Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shares have been powering on, with a gain...

분석 기사 • Feb 12

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) just released its latest quarterly report and things are not looking...

분석 기사 • Aug 13

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

The latest analyst coverage could presage a bad day for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), with the analysts...

이익 및 매출 성장 예측

NasdaqGS:ENTA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
9/30/2028	76	-62	1	-66	4
9/30/2027	68	-57	-50	-34	6
9/30/2026	69	-54	-42	29	4
3/31/2026	69	-62	-10	-8	N/A
12/31/2025	67	-72	-18	-14	N/A
9/30/2025	65	-82	-32	-19	N/A
6/30/2025	65	-92	-44	-23	N/A
3/31/2025	64	-96	-82	-55	N/A
12/31/2024	67	-105	-96	-71	N/A
9/30/2024	68	-116	-97	-79	N/A
6/30/2024	72	-115	-100	-90	N/A
3/31/2024	73	-132	-113	-107	N/A
12/31/2023	74	-138	-99	-93	N/A
9/30/2023	79	-134	-112	-103	N/A
6/30/2023	81	-132	-106	-97	N/A
3/31/2023	81	-125	-102	-95	N/A
12/31/2022	82	-121	-112	-107	N/A
9/30/2022	86	-122	-87	-85	N/A
6/30/2022	89	-120	-91	-90	N/A
3/31/2022	92	-112	-91	-90	N/A
12/31/2021	93	-101	-69	-68	N/A
9/30/2021	97	-79	-71	-70	N/A
6/30/2021	97	-84	-65	-64	N/A
3/31/2021	94	-74	-40	-39	N/A
12/31/2020	102	-58	-21	-20	N/A
9/30/2020	122	-36	6	7	N/A
6/30/2020	150	2	30	31	N/A
3/31/2020	176	24	35	38	N/A
12/31/2019	188	34	N/A	54	N/A
9/30/2019	205	46	N/A	71	N/A
6/30/2019	221	65	N/A	91	N/A
3/31/2019	234	78	N/A	93	N/A
12/31/2018	238	86	N/A	55	N/A
9/30/2018	207	72	N/A	29	N/A
6/30/2018	215	81	N/A	58	N/A
3/31/2018	166	52	N/A	49	N/A
12/31/2017	131	34	N/A	54	N/A
9/30/2017	103	18	N/A	53	N/A
6/30/2017	40	-21	N/A	-7	N/A
3/31/2017	46	-13	N/A	-4	N/A
12/31/2016	50	-10	N/A	9	N/A
9/30/2016	88	22	N/A	36	N/A
6/30/2016	90	29	N/A	36	N/A
3/31/2016	87	33	N/A	23	N/A
12/31/2015	132	63	N/A	112	N/A
9/30/2015	161	79	N/A	77	N/A
6/30/2015	149	68	N/A	74	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ENTA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ENTA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ENTA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ENTA 의 수익(연간 17.5%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ENTA 의 수익(연간 17.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ENTA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/21 07:49
종가	2026/05/21 00:00
수익	2026/03/31
연간 수익	2025/09/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Enanta Pharmaceuticals, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Enanta Pharmaceuticals 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Consensus estimates of losses per share improve by 19%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Price target decreased by 8.6% to US$18.50

Price target increased by 7.2% to US$20.50

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

Consensus EPS estimates fall by 33%

Recent updates

Consensus estimates of losses per share improve by 19%

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. to Report Q3, 2026 Results on Aug 10, 2026

Second quarter 2026 earnings: EPS exceeds analyst expectations

Enanta Pharmaceuticals Inc Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978

Price target decreased by 8.6% to US$18.50

Price target increased by 7.2% to US$20.50

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2026 Results on May 11, 2026

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 11, 2026

Enanta Pharmaceuticals, Inc. Provides Update on Its Research and Development Programs

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Consensus EPS estimates fall by 33%

President recently sold US$67k worth of stock

President notifies of intention to sell stock

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Consensus EPS estimates upgraded to US$2.30 loss

Full year 2025 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 09, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30%

Enanta Pharmaceuticals, Inc. Presents New Data for Zelicapavir, its N-Protein Inhibitor and EDP-323, L-Protein Inhibitor

New major risk - Shareholder dilution

Price target increased by 9.8% to US$19.14

Enanta Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Enanta Pharmaceuticals Reports Positive Topline Results from Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus in High-Risk Adults

New major risk - Share price stability

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Financial and Administrative Officer

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Enanta Pharmaceuticals, Inc. Announces Executive Changes on August 26, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2025 Results on Nov 17, 2025

New major risk - Revenue and earnings growth

Enanta Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Label Expansion for MAVYRET (Glecaprevir/Pibrentasvir), Oral Pangenotypic Direct Acting Antiviral (DAA) Therapy

Consensus EPS estimates upgraded to US$3.73 loss, revenue downgraded

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Price target increased by 12% to US$17.00

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2025 Results on Aug 11, 2025

New minor risk - Market cap size

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

President recently bought US$256k worth of stock

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

New minor risk - Share price stability

Price target decreased by 8.6% to US$15.43

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q2, 2025 Results on May 12, 2025

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 13, 2025

New major risk - Revenue and earnings growth

Price target decreased by 13% to US$15.75

Enanta Pharmaceuticals Announces Positive Topline Results from First-In-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Price target decreased by 7.6% to US$18.13

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

Full year 2024 earnings: EPS and revenues miss analyst expectations

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

New major risk - Revenue and earnings growth

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Senior VP & Chief Medical Officer notifies of intention to sell stock

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Insider notifies of intention to sell stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024